文献速递新生儿儿童呼吸儿童心血管与肾脏

定义新生儿持续性肺动脉高压的典型病程:何时应考虑不可逆病因

Defining the Typical Course of Persistent Pulmonary Hypertension of the Newborn: When to Think Beyond Reversible Causes.
PubMed 文献 · J Pediatr · 2024-05-31

单中心回顾性队列研究纳入2015至2020年胎龄≥35周、临床诊断PPHN的新生儿,按病因分为围产期与胎儿发育性两组,比较治疗启动、停用及持续时间。围产期PPHN缓解更快,至10日龄时停用正性肌力药、脱离ECLS、拔管及超声肺动脉高压缓解的比例均显著更高。第二周仍需靶向治疗的不典型病程应进一步排查胎儿发育性病因。

要点

  • 围产期病因PPHN占72%,胎儿发育性病因占28%。
  • 10日龄时围产期组停正性肌力药98% vs 29%,拔管75% vs 37%。
  • 第二周仍需靶向治疗提示应排查胎儿发育性病因。

核心结论

  • 围产期病因所致PPHN的缓解比胎儿发育性病因所致PPHN更迅速。
  • 第二周仍需持续靶向治疗的不典型PPHN病程,应进一步检查胎儿发育性病因。

研究设计与样本

  • 单中心回顾性队列研究,纳入2015至2020年在本院出生或转诊、胎龄≥35周且电子病历临床诊断PPHN的新生儿。
  • 排除复杂先天性心脏病和先天性膈疝;按PPHN病因分为围产期组与胎儿发育性组,使用收集时全部可用数据进行分组。
  • 主要结局为体外生命支持、机械通气、补充氧、吸入一氧化氮、正性肌力支持及前列腺素E1的启动日龄、停用日龄和总持续时间;次要结局为超声肺动脉高压缓解日龄。
  • 组间比较采用t检验,采用Kaplan-Meier曲线描述并以log-rank检验比较各治疗停用时间。

主要发现

  • 至10日龄,围产期组停用正性肌力药比例高于胎儿发育性组(98% vs 29%,P < .01)。
  • 至10日龄,围产期组脱离体外生命支持比例高于胎儿发育性组(100% vs 0%,P < .01)。
  • 至10日龄,围产期组拔管比例高于胎儿发育性组(75% vs 37%,P < .01)。
  • 至10日龄,围产期组超声肺动脉高压缓解比例高于胎儿发育性组(35% vs 7%,P = .02)。

临床怎么用

  • 对生后第二周仍需靶向治疗(如正性肌力药、机械通气、吸入一氧化氮等)的PPHN患儿,应警惕胎儿发育性病因并进一步评估。
  • 围产期病因PPHN患儿多数在生后10天内可停用正性肌力药、脱离体外生命支持、拔管并出现超声肺动脉高压缓解。

局限性

  • 本研究为单中心回顾性队列研究。
  • 研究仅纳入胎龄≥35周且临床诊断PPHN的新生儿,并排除了复杂先天性心脏病和先天性膈疝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the typical clinical course of reversible persistent pulmonary hypertension of the newborn (PPHN) from perinatal etiologies and compare that with the clinical course of PPHN due to underlying fetal developmental etiologies. STUDY DESIGN: This was a single-center, retrospective cohort study of liveborn newborns either born or transferred to our facility for higher level of care between 2015 and 2020 with gestational age ≥35 weeks and a clinical diagnosis of PPHN in the electronic health record. Newborns with complex congenital heart disease and congenital diaphragmatic hernia were excluded. Using all data available at time of collection, newborns were stratified into 2 groups by PPHN etiology - perinatal and fetal developmental causes. Primary outcomes were age at initiation, discontinuation, and total duration of extracorporeal life support, mechanical ventilation, supplemental oxygen, inhaled nitric oxide, inotropic support, and prostaglandin E1. Our secondary outcome was age at echocardiographic resolution of pulmonary hypertension. Groups were compared by t-test. Time-to-event Kaplan Meier curves described and compared (log-rank test) discontinuation of each therapy. RESULTS: Sixty-four (72%) newborns had perinatal etiologies whereas 24 (28%) had fetal developmental etiologies. The resolution of perinatal PPHN was more rapid compared with fetal developmental PPHN. By 10 days of age, more neonates were off inotropes (98% vs 29%, P < .01), decannulated from extracorporeal life support (100% vs 0%, P < .01), extubated (75% vs 37%, P < .01), and had echocardiographic resolution of PH (35% vs 7%, P = .02). CONCLUSIONS: An atypical PPHN course, characterized by persistent targeted therapies in the second week of life, warrants further work-up for fetal developmental causes.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Tsoi SM, Steurer M, Nawaytou H, et al. Defining the Typical Course of Persistent Pulmonary Hypertension of the Newborn: When to Think Beyond Reversible Causes. J Pediatr. 2024. PMID: 38823627. doi:10.1016/j.jpeds.2024.114131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。